+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ADMA Biologics Inc - logo

ADMA Biologics is a late stage biopharmaceutical company that develops specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. ADMA Biologics was founded in 2004 and is based in Ramsey, New Jersey.

Immunoglobulins Market - Global Outlook & Forecast 2021-2026 - Product Thumbnail Image

Immunoglobulins Market - Global Outlook & Forecast 2021-2026

  • Report
  • September 2021
  • 262 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 319 Pages
  • Global
From
From
From
From
From
Intravenous Immunoglobulin Global Market Report 2024 - Product Thumbnail Image

Intravenous Immunoglobulin Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
From
Immunoglobulins Global Market Report 2024 - Product Thumbnail Image

Immunoglobulins Global Market Report 2024

  • Report
  • December 2023
  • 200 Pages
  • Global
From
Primary Immune Deficiency (PID) - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Immune Deficiency (PID) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • March 2024
  • 1000 Pages
  • Global
From
Primary Immune Deficiency (PID) - Pipeline Review, H2 2020 - Product Thumbnail Image

Primary Immune Deficiency (PID) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 134 Pages
  • Global
From
From
Loading Indicator